Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy

Highlights • PD-1/PD-L1 blockades present a new paradigm shift in immunotherapy for cancer. • It is crucial to identify a biomarker predicting the response to checkpoint blockades. • PD-L1 is an important and widely-explored predictive biomarker. • There are many challenges to overcome when examinin...

Full description

Saved in:
Bibliographic Details
Published inCancer treatment reviews Vol. 41; no. 10; pp. 868 - 876
Main Authors Meng, Xiangjiao, Huang, Zhaoqin, Teng, Feifei, Xing, Ligang, Yu, Jinming
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 01.12.2015
Subjects
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized - therapeutic use
Antineoplastic Agents - therapeutic use
B7-H1 Antigen - antagonists & inhibitors
B7-H1 Antigen - metabolism
Biomarkers
Biomarkers, Tumor - metabolism
Cell Cycle Checkpoints
Hematology, Oncology and Palliative Medicine
Humans
Immunologic Factors - therapeutic use
Immunotherapy
Ipilimumab
Neoplasms - drug therapy
Neoplasms - metabolism
PD-1
PD-L1
Prognosis
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Programmed Cell Death 1 Receptor - metabolism
Response
Response
PD-L1
Biomarkers
PD-1
Immunotherapy
Online AccessGet full text

Cover

More Information
Summary:Highlights • PD-1/PD-L1 blockades present a new paradigm shift in immunotherapy for cancer. • It is crucial to identify a biomarker predicting the response to checkpoint blockades. • PD-L1 is an important and widely-explored predictive biomarker. • There are many challenges to overcome when examining PD-L1 as a predictive biomarker. • Gene analysis might be new approach for judging the potential clinical benefit.
ISSN:0305-7372
1532-1967
DOI:10.1016/j.ctrv.2015.11.001